Predicted protein targets (top 11)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | USP2 | O75604 | 1/20 | 0.49 |
| ▸ | SMN1; SMN2 | Q16637 | 1/20 | 0.49 |
| ▸ | MAPK1 | P28482 | 1/20 | 0.46 |
| ▸ | GPR119 | Q8TDV5 | 6/20 | 0.44 |
| ▸ | KDM4E | B2RXH2 | 1/20 | 0.43 |
| ▸ | MAPT | P10636 | 1/20 | 0.43 |
| ▸ | THRB | P10828 | 1/20 | 0.43 |
| ▸ | HPGD | P15428 | 1/20 | 0.42 |
| ▸ | POLB | P06746 | 1/20 | 0.41 |
| ▸ | HTT | P42858 | 1/20 | 0.41 |
| ▸ | ATM | Q13315 | 1/20 | 0.41 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL1225127 | 0.89 | USP2 (0.58) | USP2SMN1; SMN2MAPK1GPR119KDM4E | |
| SCHEMBL587550 | 0.89 | USP2 (0.58) | USP2SMN1; SMN2MAPK1GPR119KDM4E | |
| SCHEMBL12005408 | 0.89 | USP2 (0.58) | USP2SMN1; SMN2MAPK1GPR119KDM4E | |
| SCHEMBL8286 | 0.89 | USP2 (0.58) | USP2SMN1; SMN2MAPK1GPR119KDM4E | |
| Benzene SCHEMBL29155321 | 0.88 | USP2 (0.53) | USP2SMN1; SMN2MAPK1GPR119KDM4E | |
| Ammonia Solution, Strong SCHEMBL18035416 | 0.88 | USP2 (0.56) | USP2SMN1; SMN2MAPK1GPR119KDM4E | |
| SCHEMBL2220355 | 0.88 | USP2 (0.56) | USP2SMN1; SMN2MAPK1KDM4EMAPT | |
| Hydrochloric Acid SCHEMBL1904026 | 0.88 | USP2 (0.56) | USP2SMN1; SMN2MAPK1GPR119KDM4E | |
| Hydrochloric Acid SCHEMBL4141237 | 0.88 | USP2 (0.56) | USP2SMN1; SMN2MAPK1GPR119KDM4E | |
| SCHEMBL14653343 | 0.88 | USP2 (0.56) | USP2SMN1; SMN2MAPK1GPR119KDM4E |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 6 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20170067045-A1 | PEPTIDE LIBRARIES | BICYCLE THERAPEUTICS LIMITED (GB) | 2017-03-09 | — | — | US | disclosed |
| US-9518081-B2 | Peptide libraries | BICYCLE THERAPEUTICS LIMITED (GB) | 2016-12-13 | — | — | US | disclosed |
| EP-2464727-B1 | PEPTIDE LIBRARIES | BICYCLE THERAPEUTICS LTD (GB) | 2014-11-19 | — | — | EP | disclosed |
| US-20120172235-A1 | PEPTIDE LIBRARIES | MEDICAL RESEARCH COUNCIL (GB) | 2012-07-05 | — | — | US | disclosed |
| EP-2464727-A2 | PEPTIDE LIBRARIES | Medical Research Council (GB) | 2012-06-20 | — | — | EP | disclosed |
| WO-2011018227-A2 | PEPTIDE LIBRARIES | MEDICAL RESEARCH COUNCIL (GB) | 2011-02-17 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20120172235-A1 | PEPTIDE LIBRARIES | MICA, SPPL2B, PTMS | USP2 2009/4885SMN1; SMN2 3902/4885MAPK1 3218/4885 |
| US-20170067045-A1 | PEPTIDE LIBRARIES | MICA, SPPL2B, PTMS | USP2 2009/4885SMN1; SMN2 3902/4885MAPK1 3218/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.